Haijing Guan

1.3k total citations · 1 hit paper
20 papers, 778 citations indexed

About

Haijing Guan is a scholar working on Economics and Econometrics, Epidemiology and General Health Professions. According to data from OpenAlex, Haijing Guan has authored 20 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 5 papers in Epidemiology and 3 papers in General Health Professions. Recurrent topics in Haijing Guan's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Pharmaceutical Economics and Policy (4 papers) and Economic and Financial Impacts of Cancer (3 papers). Haijing Guan is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Pharmaceutical Economics and Policy (4 papers) and Economic and Financial Impacts of Cancer (3 papers). Haijing Guan collaborates with scholars based in China, Canada and United States. Haijing Guan's co-authors include Xuejing Jin, Nan Luo, Kim Rand, Gordon Liu, LI Ming-hui, Ting Zhou, Aixia Ma, Yao Zhang, Mingjun Rui and Xiaomo Xiong and has published in prestigious journals such as Quality of Life Research, Frontiers in Pharmacology and BMC Cancer.

In The Last Decade

Haijing Guan

18 papers receiving 775 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estimating an EQ-5D-5L Value Set for China

2017 418 citations Nan Luo, Gordon Liu et al. Value in Health profile →

Peers

Countries citing papers authored by Haijing Guan

Since Specialization

Citations

This map shows the geographic impact of Haijing Guan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haijing Guan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haijing Guan more than expected).

Fields of papers citing papers by Haijing Guan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haijing Guan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haijing Guan. The network helps show where Haijing Guan may publish in the future.

Co-authorship network of co-authors of Haijing Guan

This figure shows the co-authorship network connecting the top 25 collaborators of Haijing Guan. A scholar is included among the top collaborators of Haijing Guan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haijing Guan. Haijing Guan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Regulatory and clinical outcomes of priority-reviewed innovative cancer drugs in China between 2015 and 2024: an observational study 2025 ·BMC Cancer ·(unknown), Nan Peng, (unknown), (unknown), Pengcheng Liu, Haijing Guan, Dongning Yao	0
2	Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China 2024 ·Journal of Medical Economics ·Yin Shi, Yanwu Zhou, (unknown), Haijing Guan, (unknown)	4
3	Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey 2024 ·Value in Health ·Gordon G. Liu, Haijing Guan, Nan Peng, Shitong Xie, (unknown), Larry Z. Liu, Yanbing Zhou, Huajie Jin	4
4	Cost-effectiveness analysis of 11 pharmacotherapies for recurrent glioblastoma in the USA and China 2024 ·Therapeutic Advances in Medical Oncology ·(unknown), (unknown), Haijing Guan, Zhigang Zhao	0
5	Impact of competition on reimbursement decisions for cancer drugs in China: an observational study 2024 ·The Lancet Regional Health - Western Pacific ·Haijing Guan, (unknown), (unknown), (unknown), Aning Sun, (unknown), (unknown), (unknown)	2
6	Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis 2023 ·Frontiers in Pharmacology ·Yanan Xu, Haijing Guan, Kefu Yu, Nan Ji, Zhigang Zhao	4
7	Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China 2022 ·Frontiers in Oncology ·Haijing Guan, Chunping Wang, Chen Chen, Sheng Han, Zhigang Zhao	5
8	Rural population’s preferences matter: a value set for the EQ-5D-3L health states for China’s rural population 2022 ·Health and Quality of Life Outcomes ·Gordon G. Liu, Haijing Guan, Xuejing Jin, Han Zhang, Samantha A. Vortherms, Hongyan Wu	14
9	Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China 2022 ·Advances in Therapy ·Haijing Guan, Chunping Wang, Zhigang Zhao, Sheng Han	13
10	Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review 2021 ·Frontiers in Public Health ·Ting Zhou, Haijing Guan, (unknown), Yao Zhang, Mingjun Rui, Aixia Ma	121
11	Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China 2021 ·Advances in Therapy ·Ting Zhou, (unknown), Haijing Guan	6
12	Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China 2021 ·Frontiers in Public Health ·Ting Zhou, (unknown), Haijing Guan, Rui Meng, Zijing Wang	6
13	Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing 2020 ·Quality of Life Research ·Juan Zhu, Xinxin Yan, Chengcheng Liu, Hong Wang, Le Wang, Su‐Mei Cao, Xianzhen Liao, Yunfeng Xi, Yong Bae Ji, Lin Lei, Haifan Xiao, Haijing Guan, Wenqiang Wei, Min Dai, Wanqing Chen, Jufang Shi	31
14	Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non–Small Cell Lung Cancer in China 2019 ·Clinical Therapeutics ·Haijing Guan, Gordon G. Liu, Feng Xie, (unknown), Luwen Shi	22
15	Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China 2019 ·Advances in Therapy ·Haijing Guan, (unknown), (unknown), Sheng Han, Luwen Shi	16
16	Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL) 2018 ·Health and Quality of Life Outcomes ·Xuejing Jin, Gordon G. Liu, Hertzel C. Gerstein, Mitchell Levine, (unknown), Haijing Guan, Hongchao Li, Feng Xie	19
17	Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community‐based survey in China 2018 ·Diabetes/Metabolism Research and Reviews ·Xuejing Jin, Gordon G. Liu, Hertzel C. Gerstein, Mitchell Levine, Haijing Guan, Hongchao Li, Feng Xie	11
18	The quality of life in Chinese population with chronic non-communicable diseases according to EQ-5D-3L: a systematic review 2018 ·Quality of Life Research ·Ting Zhou, Haijing Guan, (unknown), Xiaomo Xiong, Aixia Ma	58
19	Estimating an EQ-5D-5L Value Set for China breakdown → 2017 ·Value in Health ·Nan Luo, Gordon Liu, LI Ming-hui, Haijing Guan, Xuejing Jin, Kim Rand	418
20	Is bad living better than good death? Impact of demographic and cultural factors on health state preference 2015 ·Quality of Life Research ·Xuejing Jin, (unknown), Nan Luo, Hongchao Li, Haijing Guan, (unknown)	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact